Functional Lung Imaging With DECT and 4DCT

Completed

• Conditions: Non Small Cell Lung Cancer
• Interventions: Procedure: contrast enhanced 4DCT

• Registration Number: NCT04702607
• Lead Sponsor: Abramson Cancer Center at Penn Medicine

Brief Summary

The basic premise of this pilot study is to enroll 40 patients over 3 years who have Stage II, III, or IV non-small cell lung cancer and are planned for definitive treatment with concurrent chemoradiation where a contrast enhanced 4DCT is planned.

Detailed Description

Not available

Study Timeline

• Study Start: 2021-01-02
• Study First Submitted: 2021-01-07
• Study First Submitted QC: 2021-01-07
• Study First Posted: 2021-01-11
• Primary Completion: 2024-10-05
• Study Completion: 2024-10-05
• Status Verified: 2024-11
• Last Update Submitted: 2024-11-04
• Last Update Posted: 2024-11-05

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 40

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
contrast enhanced 4DCT	contrast enhanced 4DCT	-

Primary Outcome Measures

Name	Time	Method
evaluate the reproducibility of PBV DECT imaging and 4DCT derived lung ventilation for evaluating lung function	3 years
correlate changes of PBV DECT and 4DCT lung function images seen at ~6 months with radiation dose and with patient reported outcome quality of life	3 years

Secondary Outcome Measures

Name	Time	Method
• To propose a novel biologic (i.e. functional) dose volume algorithm to reduce PBV and 4DCT lung function changes	3 years

Trial Locations

Locations (1)

Abamson Cancer Center of the University of Pennsylvania; 🇺🇸 Philadelphia, Pennsylvania, United States